According to recent free report from investing newsletter editor Paul Mampilly, there’s an ongoing megatrend in medicine that is one of the biggest breakthroughs in history. Most people have not heard of it yet, even doctors who are too busy to keep up with advances in medical technology. However, it’s going to dramatically change the way we treat many diseases, including such difficult ones as cancer, Parkinson’s, diabetes, arthritis and Alzheimer’s.
Doctors have various standard drugs they use, but none of them really cure anybody. Most treatments today just reduce symptoms or slow down the disease’s progression. Standard treatment options are all done on a one size for all basis. Yet some people respond to the drugs better than do other patients. Before long, doctors will look at the patient’s unique genomic profile, their DNA, and know which drugs and treatments will be effective against that patient’s disease, and which will not. It’s called precision medicine because the treatments are tailored specifically to the patient.
And Paul Mampilly has identified a small biotech firm that is in the forefront of this precision medicine megatrend. He promises to reveal the name of it to people who subscribe to his Profits Unlimited newsletter, published by Banyan Hill.
On Wall Street, Paul Mampilly is still a legend. He started out as an assistant portfolio manager for Bankers Trust, but his knack for finding winners soon made him a star. He went to work for Deutsche Bank and ING, choosing stocks for accounts of millions of dollars. The $6 billion hedge fund Kinetics Asset Management recruited him as a manager. Paul Mampilly grew it to $25 billion, averaging 26% returns in the years he ran it. Barron’s listed that fund as one of their “World’s Best” hedge funds.
Thanks to these impressive performances, the Templeton Foundation invited him to participate in their prestigious investing competition, in honor of their founder, the legendary John Templeton. They gave him $50 million to invest. In just two years he turned that into $78 million, a 76% return. And that was during 2008-2009, the worst financial crisis since the Great Depression. General prices in all asset classes fell during that period, including real estate, stocks and bonds. Yet Paul Mampilly made a $28 million profit without shorting anything. However, he grew tired of making the wealthy even more wealthy. Now his mission is to help ordinary Americans grow their retirement savings.
Contact Paul Mampilly: seekingalpha.com/user/48491120/stocktalks